A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
← catalyst calendarNCT06782282 · readout in 72 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
22,234,435actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-20 | actual | When the study began enrolling |
| Primary completion | 2026-10-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Community-Acquired Pneumonia (CAP)
Primary outcomes
what the primary-completion date above is the date OFWeighted PCV20 vaccine effectiveness (VE) against Invasive Pneumococcal Disease (IPD)
measured Time to pneumococcal vaccination, disenrollment from Medicare FFS Parts A or B, enrollment in Medicare Part C, death, or IPD up to 24 months
Weighted PCV20 VE against Pneumococcal Pneumonia (PP)
measured Time to pneumococcal vaccination, disenrollment from Medicare FFS Parts A or B, enrollment in Medicare Part C, death, or PP up to 24 months
Absolute difference in the incidence of PP by PCV20 vaccination status
measured Time to pneumococcal vaccination, disenrollment from Medicare FFS Parts A or B, enrollment in Medicare Part C, death, or PP up to 24 months
Weighted PCV20 VE against all cause pneumonia (ACP)
measured Time to pneumococcal vaccination, disenrollment from Medicare FFS Parts A or B, enrollment in Medicare Part C, death, or ACP up to 24 months
Absolute difference in incidence of ACP by PCV20 vaccination status
measured Time to pneumococcal vaccination, disenrollment from Medicare FFS Parts A or B, enrollment in Medicare Part C, death, or ACP up to 24 months
Absolute difference in the incidence of IPD by PCV20 vaccination status
measured Time to pneumococcal vaccination, disenrollment from Medicare FFS Parts A or B, enrollment in Medicare Part C, death, or IPD up to 24 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed